Evotec's Core Business Surges 28% Even as Delayed Milestones Force Second Profit Warning
Published on 07/27/2026 at 05:52 | Redaktion boerse-global.de
The disconnect between Evotec's operational engine and its financial results has rarely been starker. While the German drug discovery firm's shares languish at €3.45 — down 36.66% year-to-date and hovering near a 52-week low of €3.19 — the underlying business in its core Discovery & Preclinical Development segment posted net revenue growth of roughly 28% year-on-year in the first half. That figure, adjusted for strategic partnerships, tells a story that the stock price refuses to acknowledge.
RBC analyst Charles Weston has highlighted that order momentum in the base business actually accelerated during the period, with Evotec gaining market share in its bread-and-butter drug research operations. Yet the market's attention remains fixed on a very different narrative: the company's second guidance revision in just a few months.
The Timing Trap
Evotec's mid-July forecast overhaul was brutal on paper. Management now expects a negative adjusted Group EBITDA of between €70 million and €105 million for fiscal 2026, a dramatic reversal from the prior target of a positive result ranging from zero to €40 million. Revenue guidance was slashed from €700-780 million to €570-610 million.
The explanation, however, lies not in evaporating demand but in calendar mechanics. Roughly 85% of the revenue shortfall relative to original planning stems from milestone payments that failed to materialize on schedule. About 40% of those revenues have slipped into 2027, while another 45% have moved beyond the fourth quarter of 2026. The remaining 15% reflects delayed strategic partnership closings.
Should investors sell immediately? Or is it worth buying Evotec?
First-half preliminary figures underscore the strain: group revenue of approximately €300.1 million produced an adjusted EBITDA of roughly minus €42.7 million. But the core business itself continues to generate healthy top-line expansion — the problem is purely one of when cash lands in the bank account, not whether the work is being done.
Analyst Ranks Split
The market's response to the second warning within months was swift and unforgiving. Deutsche Bank analysts cut their price target to €3.50 on July 16, while Berenberg downgraded the stock from "Buy" to "Hold" the same day, slashing its target to €3.60. US-based analysts covering the American depositary receipts took an even more cautious stance.
The technical picture reinforces the bearish mood. The relative strength index stands at 24.8, deep in oversold territory, while the share price sits 25.80% below its 50-day moving average of €4.65. Market participants are now debating whether the erosion of trust over recent months has already priced in operational setbacks that the core business data doesn't support.
Buying Time With €465 Million
CEO Christian Wojczewski is betting that the "Horizon" cost-cutting program will bridge the credibility gap. The initiative targets annual savings of roughly €75 million by the end of 2027, and the company's liquidity position of €465.6 million as of June 30 provides a substantial cushion to finance the transition.
On the technology front, Evotec continues to invest. Its subsidiary Just – Evotec Biologics launched "J.TRAIN" in late June, a turnkey solution for continuous biologics manufacturing. The group also announced it would consolidate global travel and expense management through an AI-powered platform from Navan, and filled a new role of Head of Global In Silico and AI to sharpen its computational drug discovery capabilities.
Evotec at a turning point? This analysis reveals what investors need to know now.
Skeptics point to the high cash burn rate and structural profitability questions that the delayed milestones have exposed. Optimists counter that a business growing its core revenue by 28% while trading near its 52-week low represents a mispriced opportunity.
The full audited half-year report due in August 2026 will provide the next major data point. Investors will scrutinize whether the core growth trajectory held steady through the period and how much of the Horizon savings have already begun showing up in the balance sheet. Until then, the €3.19 level — the stock's 52-week trough — remains the critical line in the sand.
Ad
Evotec Stock: New Analysis - 27 July
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
